Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aventis Pharma: Going strong - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Aug 8, 2003

    Aventis Pharma: Going strong

    MNC pharma major, Aventis Pharma (formerly Hoechst Marion) has announced its June quarter results recently. The company recorded a 9% increase in the topline and a strong 37% growth in the bottomline. For the first half of FY04 (1HFY04) Aventis registered a 7% increase in revenues and net profits surged by 52%. In this context, let us briefly evaluate the performance of the company.

    (Rs m) 2QFY03 2QFY04 % Change 1HFY03 1HFY04 % Change
    Net Sales 1,603 1,753 9.4% 2,981 3,200 7.3%
    Other Income 17 40 135.3% 42 68 61.9%
    Expenditure 1,343 1,402 4.4% 2,539 2,627 3.5%
    Operating Profit (EBDIT) 260 351 35.0% 442 573 29.6%
    Operating Profit Margin (%) 16.2% 20.0%   14.8% 17.9%
    Interest 1 - -100.0% 3 - -
    Depreciation 37 40 8.1% 75 80 6.7%
    Profit before Tax 239 351 46.9% 406 561 38.2%
    Extraordinary Items 18 (5) - 1 60 -
    Tax 87 113 29.9% 130 199 53.1%
    Profit after Tax/(Loss) 170 233 37.1% 277 422 52.3%
    Net profit margin (%) 10.6% 13.3%   9.3% 13.2%  
    No. of Shares (eoy) (m) 23.0 23.0   23.0 23.0  
    Diluted Earnings per share* 29.5 40.5   24.1 36.6  
    P/E (at current price) 10.6     11.7  
    * annualised            

    If we exclude extraordinary item, bottomline growth in the June quarter surges to 57% YoY. If we do the same for the half yearly result, bottomline growth stands at over 31%. This indicates that the June quarter has operationally been much better than the company’s March quarter.

    For 2QFY04, Aventis has recorded a steady growth in the topline. While the domestic revenues grew by 8.5%, exports registered a 12% rise. The company’s strategic brands grew by a strong 17%. Aventis’s strong brand equity and secondary demand for its brands like Cardace (27% rise), Targocid (24%), Clexane (23%), Amaryl (20%) & Allegra (17%) were the key reasons for this strong growth. However, the revenues from ‘Tavanic’ have seen a steady decline (26% drop). Consequently, the company has gradually reduced its investments in this brand. Among other brands, Combiflam (27%), Rabipur (20%), and Trental (36%) continued to maintain leadership position in their respective segments. While, Avil and Daonil registered single-digit growths, Soframycin recorded negative growth, but remained leader in its category.

    A favourable domestic product mix coupled with an increase in the contribution from exports has helped Aventis improve its operating margins. Improvement in operating efficiencies and a sharp increase in the other income has helped Aventis record an increase in the net margins.

    In July ’03, Aventis has launched Lantus, an insulin glargine used for the treatment of diabetes. The product has been already launched in Germany and USA. The company is in the process of obtaining regulatory clearance for launching this product in India. Actonel, a product for osteoporosis, has also been successfully introduced in many countries and the company is likely to take a decision on its launch in India soon. The launch of these products could benefit from APL’s brand name and franchise network. This could further improve the performance of the company.

    At Rs 429 the Aventis stock trades at a P/E of 11.7x its annualised 1HFY04 earnings. Historically, the stock has traded at a discount to its MNC peers owing to some Indian promoter related issues. Considering the relatively new product portfolio, high exposure in the lifestyle segments and strong parent product pipeline, the long-term prospects of the company seem bright.



    Equitymaster requests your view! Post a comment on "Aventis Pharma: Going strong". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)


    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts